Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy | Zendy

Oluwaseun O. Akinduro | Zendy; Paola Suárez-Meade | Zendy; Diogo MonizGarcia | Zendy; Desmond Brown | Zendy; Rachel Sarabia-Estrada | Zendy; Steven Attia | Zendy; Ziya L. Gokaslan | Zendy; Alfredo QuiñonesHinojosa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy

Author(s) -

Oluwaseun O. Akinduro,

Paola Suárez-Meade,

Diogo MonizGarcia,

Desmond Brown,

Rachel Sarabia-Estrada,

Steven Attia,

Ziya L. Gokaslan,

Alfredo QuiñonesHinojosa

Publication year - 2021

Publication title -

targeted oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.697

H-Index - 40

eISSN - 1776-260X

pISSN - 1776-2596

DOI - 10.1007/s11523-021-00814-5

Subject(s) - medicine , chordoma , clinical trial , targeted therapy , oncology , radiation therapy , progression free survival , combination therapy , surgery , overall survival , cancer

Chordoma is a rare but devastating tumor that arises in the cranial skull base or spine. There are currently no US Food and Drug Administration-approved targeted therapies for chordoma, and little understanding of whether using more than one therapy has benefit over monotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research